Cholesterol, a water insoluble compound, is a major player in the etiology of atherosclerosis. Cholesterol accumulates in plaques in the arterial wall causing obstructed blood flow leading to heart attacks and strokes. Despite the success of the statin class of cholesterol-lowering drugs, which reduce plasma LDL-cholesterol, there remains an unfulfilled need for complementary therapies that promote the removal of cholesterol from atherosclerotic lesions and its transfer to the liver for disposal. We identified a bacterial protein, serum opacity factor (SOF) that at low doses (0.004 mg) rapidly (6 min) and profoundly reduces by half the plasma cholesterol in mice. On the basis of studies with liver cells, we learned that SOF treatment promotes hepatic cholesterol uptake by multiple receptors that bind to a plasma protein, apolipoprotein E. Our plans are to move these discoveries closer to human therapy by completion of several objectives. The first is to show in primary human hepatocytes that the mechanisms for cholesterol removal are as efficient as they are in hepatic cell lines and in mouse liver cells. The second is to determine the contributions of each relevant liver receptor to cholesterol removal. This information would be useful in making choices about the most appropriate co therapy, e.g., a statin. Third, we will show that SOF increases the transfer of cholesterol from macrophages, an important cell type in all stages of atherosclerosis, to the liver for disposal. Lastly, we will show that SOF reverses atherosclerosis in mice. Completion of these objectives would pave the way to future studies in non human primates and ultimately in high risk patients with atherosclerosis. Methods: Radio trace cholesterol uptake and removal by liver cells in response to SOF;use chromatographic methods to show in cells and mice that SOF promotes conversion of macrophage-cholesterol to water-soluble bile salts that enter the intestine for disposal;characterize in mice the changes in response to SOF in the quantity and quality of arterial lesions by chemical analysis and morphometry.

Public Health Relevance

Low plasma high density lipoproteins (HDL)-cholesterol, due to impaired reverse cholesterol transport (RCT), is a serious disorder and public health problem for which current treatments are inadequate. We discovered that streptococal serum opacity factor enhances multiple RCT steps in vitro and in vivo. We plan to move this discovery toward a new therapy by determining whether this process improves RCT and inhibits and/or reverses atherosclerosis in cell and mouse models of lipid disorders and atherosclerosis.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL056865-14
Application #
8491782
Study Section
Integrative Nutrition and Metabolic Processes Study Section (INMP)
Program Officer
Fleg, Jerome
Project Start
1997-04-01
Project End
2015-12-31
Budget Start
2014-01-01
Budget End
2014-12-31
Support Year
14
Fiscal Year
2014
Total Cost
$582,620
Indirect Cost
$201,433
Name
Methodist Hospital Research Institute
Department
Type
DUNS #
185641052
City
Houston
State
TX
Country
United States
Zip Code
77030
Pownall, Henry; Moore, Kathryn (2014) Commentary on fatty acid wars: the diffusionists versus the translocatists. Arterioscler Thromb Vasc Biol 34:e8-9
Gillard, Baiba K; Raya, Joe L; Ruiz-Esponda, Raul et al. (2013) Impaired lipoprotein processing in HIV patients on antiretroviral therapy: aberrant high-density lipoprotein lipids, stability, and function. Arterioscler Thromb Vasc Biol 33:1714-21
Wooten, Joshua S; Nambi, Preethi; Gillard, Baiba K et al. (2013) Intensive lifestyle modification reduces Lp-PLA2 in dyslipidemic HIV/HAART patients. Med Sci Sports Exerc 45:1043-50
Vasudevan, Madhuri; Tchoua, Urbain; Gillard, Baiba K et al. (2013) Modest diet-induced weight loss reduces macrophage cholesterol efflux to plasma of patients with metabolic syndrome. J Clin Lipidol 7:661-70
Auton, Matthew; Bassett, G Randall; Gillard, Baiba K et al. (2013) Free cholesterol determines reassembled high-density lipoprotein phospholipid phase structure and stability. Biochemistry 52:4324-30
Rosales, Corina; Tang, Daming; Gillard, Baiba K et al. (2011) Apolipoprotein E mediates enhanced plasma high-density lipoprotein cholesterol clearance by low-dose streptococcal serum opacity factor via hepatic low-density lipoprotein receptors in vivo. Arterioscler Thromb Vasc Biol 31:1834-41
Tchoua, Urbain; Rosales, Corina; Tang, Daming et al. (2010) Serum opacity factor enhances HDL-mediated cholesterol efflux, esterification and anti inflammatory effects. Lipids 45:1117-26
Tchoua, Urbain; Gillard, Baiba K; Pownall, Henry J (2010) HDL superphospholipidation enhances key steps in reverse cholesterol transport. Atherosclerosis 209:430-5
Courtney, Harry S; Pownall, Henry J (2010) The structure and function of serum opacity factor: a unique streptococcal virulence determinant that targets high-density lipoproteins. J Biomed Biotechnol 2010:956071
Ren, Gang; Rudenko, Gabby; Ludtke, Steven J et al. (2010) Model of human low-density lipoprotein and bound receptor based on cryoEM. Proc Natl Acad Sci U S A 107:1059-64

Showing the most recent 10 out of 50 publications